The annual Alzheimer’s research meeting known as CTAD was supposed to be a snoozefest this year. That all changed six weeks ago, when Biogen stunned the medical world by bringing an Alzheimer’s drug back from the dead — and vowed to make a detailed scientific case for the decision at the gathering this week.

On Thursday morning, Biogen will give that highly anticipated presentation — livestreamed here — detailing data from two late-stage clinical trials of its drug, known as aducanumab. It will be the highlight of CTAD, short for Clinical Trials on Alzheimer’s Disease.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy